Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 13Uterine Cervical Neoplasms 9Stomach Neoplasms 9Colorectal Neoplasms 7Fallopian Tube Neoplasms 6Carcinoma, Ovarian Epithelial 6Carcinoma, Non-Small-Cell Lung 6Neoplasm Metastasis 5Endometrial Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Lung Neoplasms 3Esophageal Neoplasms 3Triple Negative Breast Neoplasms 2Sarcoma 2Rectal Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Appendiceal Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Recurrence 1Peritoneal Neoplasms 1

Interventions

zimberelimab 1PM 01183 1Irinotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Irinotecan × Gynecologic × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡